CRP and metastatic neoplasm: The majority of enrolled patients had unfavorable prognostic baseline characteristics and had received multiple lines of previous systemic cancer therapy (including CPI), had multiple sites of metastatic disease, had elevated C-reactive protein and had tumors with negative or low PD-L1 scores (Extended Data Tables 1 and 2).